Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-201 Administered to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Rademikibart (Primary) ; Rademikibart (Primary)
- Indications Asthma; Atopic dermatitis; Nasal polyps
- Focus Adverse reactions; First in man
- 06 May 2019 Results published in the Connect Biopharma Media Release
- 06 May 2019 Status changed from active, no longer recruiting to completed, as reported in a Connect Biopharma media release.
- 09 Jan 2019 Status changed from not yet recruiting to active, no longer recruiting.